Thursday, Jun 11, 1987
South San Francisco, Calif. -- June 11, 1987 --Genentech, Inc. announced today that its foreign licensee, Boehringer Ingelheim International GmbH, has received approval to market t-PA in France for the treatment of heart attack patients.
Tissue plasminogen activator (t-PA), which will be marketed outside of North America under the trademark Actilyse, is a human protein that dissolves blood clots that cause heart attacks. It has been tested in clinical trials since early 1984. Actilyse has also been approved in the Philippines and New Zealand and is awaiting approval in more than 20 other countries around the world. Genentech will receive royalties on product sales outside of the U.S. and Canada.Genentech is a leading biotechnology company, focusing on the development, manufacture and marketing of pharmaceuticals produced by recombinant DNA technology.
# # #